A phase Ib trial of IPI-926, a hedgehog pathway inhibitor, plus gemcitabine in patients with metastatic pancreatic cancer.

被引：29
|
作者：
Richards, Donald Anthony
Stephenson, Joe
Wolpin, Brian M.
Becerra, Carlos
Hamm, John Turner
Messersmith, Wells A.
Devens, Shannon
Cushing, Jill
Schmalbach, Tess
Fuchs, Charles S.
机构：
[1] US Oncol Res LLC, The Woodlands, TX USA
[2] Texas Oncol, Tyler, TX USA
[3] Canc Ctr Carolinas, Greenville, SC USA
[4] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[5] Texas Oncol Sammons Canc Ctr Baylor, Dallas, TX USA
[6] Louisville Oncol Res, Louisville, KY USA
[7] Univ Colorado, Canc Ctr, Aurora, CO USA
[8] Infin Pharmaceut Inc, Cambridge, MA USA
[9] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 04期
关键词：
D O I：
10.1200/jco.2012.30.4_suppl.213
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
213
引用
收藏
页数：2
相关论文
共 50 条
  • [1] The safety of IPI-926, a novel hedgehog pathway inhibitor, in combination with gemcitabine in patients (pts) with metastatic pancreatic cancer.
    Stephenson, J.
    Richards, D. A.
    Wolpin, B. M.
    Becerra, C.
    Hamm, J. T.
    Messersmith, W. A.
    Devens, S.
    Cushing, J.
    Goddard, J.
    Schmalbach, T.
    Fuchs, C. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [2] A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma
    Ko, Andrew H.
    LoConte, Noelle
    Tempero, Margaret A.
    Walker, Evan J.
    Kelley, R. Kate
    Lewis, Stephanie
    Chang, Wei-Chou
    Kantoff, Emily
    Vannier, Michael W.
    Catenacci, Daniel V.
    Venook, Alan P.
    Kindler, Hedy L.
    PANCREAS, 2016, 45 (03) : 370 - 375
  • [3] A PHASE 1 STUDY OF IPI-926, AN INHIBITOR OF THE HEDGEHOG PATHWAY, IN PATIENTS (PTS) WITH ADVANCED OR METASTATIC SOLID TUMORS
    Rudin, C. M.
    Weiss, G. J.
    Chang, A.
    Gettinger, S.
    Miller, W. H.
    Eigl, B.
    Savage, A.
    Loewen, G.
    Ross, R. W.
    Jimeno, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 164 - 164
  • [4] Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors
    Jimeno, Antonio
    Weiss, Glen J.
    Miller, Wilson H., Jr.
    Gettinger, Scott
    Eigl, Bernard J. C.
    Chang, Anne Lynne S.
    Dunbar, Joi
    Devens, Shannon
    Faia, Kerrie
    Skliris, Georgios
    Kutok, Jeff
    Lewis, Karl D.
    Tibes, Raoul
    Sharfman, William H.
    Ross, Robert W.
    Rudin, Charles M.
    CLINICAL CANCER RESEARCH, 2013, 19 (10) : 2766 - 2774
  • [5] Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis
    Sasaki, Koji
    Gotlib, Jason R.
    Mesa, Ruben A.
    Newberry, Kate J.
    Ravandi, Farhad
    Cortes, Jorge E.
    Kelly, Patrick
    Kutok, Jeffery L.
    Kantarjian, Hagop M.
    Verstovsek, Srdan
    LEUKEMIA & LYMPHOMA, 2015, 56 (07) : 2092 - 2097
  • [6] Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer
    Catenacci, Daniel V. T.
    Junttila, Melissa R.
    Karrison, Theodore
    Bahary, Nathan
    Horiba, Margit N.
    Nattam, Sreenivasa R.
    Marsh, Robert
    Wallace, James
    Kozloff, Mark
    Rajdev, Lakshmi
    Cohen, Deirdre
    Wade, James
    Sleckman, Bethany
    Lenz, Heinz-Josef
    Stiff, Patrick
    Kumar, Pankaj
    Xu, Peng
    Henderson, Les
    Takebe, Naoko
    Salgia, Ravi
    Wang, Xi
    Stadler, Walter M.
    de Sauvage, Frederic J.
    Kindler, Hedy L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (36) : 4284 - +
  • [7] A phase I study of IPI-926, a novel hedgehog pathway inhibitor, in patients (pts) with advanced or metastatic solid tumors.
    Rudin, C. M.
    Jimeno, A.
    Miller, W. H.
    Eigl, B. J.
    Gettinger, S. N.
    Chang, A. L. S.
    Faia, K.
    Sweeney, J.
    Loewen, G.
    Ross, R. W.
    Weiss, G. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] A phase 2 study of IPI-926, an oral hedgehog inhibitor, in patients with myelofibrosis.
    Sasaki, Koji
    Gotlib, Jason R.
    Mesa, Ruben A.
    Ravandi, Farhad
    Cortes, Jorge E.
    Kelly, Patrick Francis
    Kutok, Jeffrey Lorne
    Kantarjian, Hagop M.
    Verstovsek, Srdan
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] Impact of the Smoothened Inhibitor, IPI-926, on Smoothened Ciliary Localization and Hedgehog Pathway Activity
    Peluso, Marisa O.
    Campbell, Veronica T.
    Harari, Joseph A.
    Tibbitts, Thomas T.
    Proctor, Jennifer L.
    Whitebread, Nigel
    Conley, James M.
    White, Kerry F.
    Kutok, Jeffery L.
    Read, Margaret A.
    McGovern, Karen
    Faia, Kerrie L.
    PLOS ONE, 2014, 9 (03):
  • [10] Hedgehog pathway inhibitor saridegib (IPI-926) increases lifespan in a mouse medulloblastoma model
    Lee, Michelle J.
    Hatton, Beryl A.
    Villavicencio, Elisabeth H.
    Khanna, Paritosh C.
    Friedman, Seth D.
    Ditzler, Sally
    Pullar, Barbara
    Robison, Keith
    White, Kerry F.
    Tunkey, Chris
    LeBlanc, Michael
    Randolph-Habecker, Julie
    Knoblaugh, Sue E.
    Hansen, Stacey
    Richards, Andrew
    Wainwright, Brandon J.
    McGovern, Karen
    Olson, James M.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (20) : 7859 - 7864
12345